By Karen E. Roman SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company, recently announced it will issue and sell shares of preferred stock in a private placement. The transaction will provide up to $130 million to SAB...

By Daniella Parra ProSomnus, Inc. (NASDAQ: OSA) said it raised $10 million in a convertible preferred equity offering led by existing investors Spring Mountain Capital and Cetus Capital, LLC, along with participation from key executives. The funding will be used...

Healthcare Edge hosted a fireside chat from the floor of the New York Stock Exchange with Marc Hedrick, M.D., President and CEO of Plus Therapeutics, Inc. (Nasdaq: PSTV). Dr. Hedrick spoke to Healthcare Edge Editor-in-Chief John Jannarone about its novel...

By Daniella Parra ProSomnus, Inc. (NASDAQ: OSA) is set to feature its precision sleep apnea devices in upcoming medical conferences, showcasing new data on the efficacy, safety and effectiveness of ProSomnus devices, it said. One study compared precision oral appliance...

By Daniella Parra Sparrow Pharmaceuticals expanded its Phase 2 clinical trial for SPI-62 in combination with prednisolone to treat polymyalgia rheumatica (PMR), the company said. The trial is exploring the potential benefits of SPI-62 in reducing the side effects of...

By Daniella Parra Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company specializing in advanced radiotherapeutics for brain cancer, said it will present data from its ReSPECT-LM clinical trial at the CPRIT Innovations in Cancer Prevention and Research Conference VI....

By Daniella Parra Plus Therapeutics, Inc. (Nasdaq: PSTV) has expanded its partnership with Biocept with an exclusive option to license a diagnostic platform for central nervous system cancer patients undergoing radiotherapy, the company said. CNSide is a proprietary assay that...

By Daniella Parra Eterna Therapeutics Inc. (Nasdaq: ERNA) is partnering with Lineage Cell Therapeutics, Inc. to develop stem cell lines for central nervous system diseases, the company said. Eterna’s mRNA gene-editing approach and Lineage’s expertise in gene editing aim to...

  By Karen E. Roman Octave Bioscience, Inc., a company offering treatment for multiple sclerosis and other neurodegenerative diseases, said it will conduct a real-world study with its sponsor Biogen (Nasdaq: BIIB) evaluating 150 patients using the Octave Precision Care Solution....

By Karen E. Roman Plus Therapeutics, Inc. (Nasdaq: PSTV) announced treatment of the first patient in Part B of a trial for the treatment of leptomeningeal metastases from solid tumors. Leptomeningeal metastases are complication of cancer in which the primary cancer spreads to...